Clinical Trial Update: Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF [Phase 2]

View source ↗

Summary

Phase 2A double-blind, placebo-controlled dose-escalation study evaluating safety, tolerability, pharmacodynamics, and pharmacokinetics of HU6 in subjects with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• HU6

Snippet

Sponsor: Rivus Pharmaceuticals, Inc. | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: COMPLETED